天津医药

天津医药 ›› 2020, Vol. 48 ›› Issue (1): 71-75.doi: 10.11958/20191721

• 综述 • 上一篇    下一篇

嵌合抗原受体T细胞免疫疗法在B细胞非霍奇金 淋巴瘤中的研究进展

赵培起，张会来△   

  1. 基金项目：国家自然科学基金资助项目（81402575） 作者单位：天津医科大学肿瘤医院淋巴瘤内科，国家肿瘤临床医学研究中心，天津市“肿瘤防治”重点实验室，天津市恶性肿瘤临床医学研 究中心（邮编300060） 作者简介：赵培起（1985），男，博士，主治医师，讲师，主要从事淋巴瘤的个体化诊断及治疗 △通讯作者 E-mail: zhlwgq@126.com
  • 收稿日期:2019-06-10 修回日期:2019-08-11 出版日期:2020-01-15 发布日期:2020-01-15
  • 通讯作者: 赵培起 E-mail:peiqizhao@126.com
  • 基金资助:
    高效智能核壳纳米递送系统介导survivin siRNA和阿霉素逆转乳腺癌多药耐药的机制研究

Research progress of chimeric antigen receptor T cell immunotherapy in B-cell non-Hodgkin lymphoma

ZHAO Pei-qi，ZHANG Hui-lai△   

  1. Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin’s Clinical Research Center for Cancer, Tianjin 300060, China △Corresponding Author E-mail: zhlwgq@126.com
  • Received:2019-06-10 Revised:2019-08-11 Published:2020-01-15 Online:2020-01-15
  • Contact: Pei-Qi ZHAO E-mail:peiqizhao@126.com

PDF (PC)

4545

摘要： 摘要：非霍奇金淋巴瘤（NHL）是最常见的血液系统恶性肿瘤，复发难治患者预后欠佳。嵌合抗原受体T细胞免 疫疗法（CAR-T）是近年来新兴的免疫治疗方法，在恶性肿瘤尤其是血液系统恶性肿瘤治疗方面取得了较多突破，尤 其是给复发难治的B细胞NHL患者带来了希望。目前，美国食品药品监督管理局（FDA）已批准两款CAR-T细胞疗 法tisagenlecleucel和axicabtagene ciloleucel，其他几种产品仍在临床试验中。本文就CAR-T的结构及其在常见B细 胞NHL中的疗效、安全性及研究趋势做一综述。

关键词: 淋巴瘤, 免疫疗法, 综述, 嵌合抗原受体T细胞

Abstract: Abstract: Non-Hodgkin lymphoma (NHL) is the most common hematological malignancy, and the prognosis of patients with relapse and refractory is poor. Chimeric antigen receptor T-cell immunotherapy (CAR-T) is a new immunotherapy method in recent years, which has made many breakthroughs in the treatment of malignant tumors, especially hematological tumors. In particular, there is hope for patients with relapsed and refractory B-cell NHL. At present, Food and Drug Administration (FDA) has approved two CAR-T cell therapy tisagenlecleucel and axicabtagene ciloleucel. Several other products are still in clinical trials. This article reviews the structure of CAR-T and its efficacy, safety and research trends in common B-cell NHL

Key words: lymphoma, immunotherapy, review, chimeric antigen receptor T cell